[1] Liu B, Wang T, Zhao HN, et al. The prevalence of hyperuricemia in China: a meta-analysis[J].BMC Public Health,2011,11(1):832.
[2]Lu X, Li X, Zhao Y,et al. Contemporary epidemiology of gout and hyperuricemia in community elderly in Beijing[J]. Int J Rheum Dis,2014,17(4): 400-407.
[3]徐熠,徐玲玲,刘静,等.中药治疗慢性痛风性关节炎的规律及其Logistic回归分析[J].世界临床药物,2013,34(8):469-471.
[4]佟金秋,马宝东,陈岩松.痛风内治法用药规律系统综述[J].实用中医内科杂志,2013, 27(10):1-2.
[5]孙雪莲, 刘渊, 周红海.牛膝总皂苷对兔膝骨关节炎软骨组织形态变化及关节液中IL-1β、TGF-β1含量的影响[J].中药新药与临床药理, 2016, 27(3): 321-326.
[6]陈光亮,吕红霞,王媛媛, 等. 萆薢牛膝总皂苷对尿酸钠诱导的大鼠急性痛风性关节炎的防治作用[J].中药药理与临床, 2010, 26(1): 34-37.
[7]陈光亮. 萆薢牛膝总皂苷防治痛风及其机制研究[D].安徽医科大学, 2005.
[8]胡雨峰,俞晶华,奚飞飞. 桂枝芍药知母汤对 CIA 大鼠关节炎的作用及其机制研究[J]. 江苏中医药,2015,47(11):76-82.
[9]Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 infammasome[J]. Nature,2006, 440(7081): 237-241.
[10]Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases[J]. Annu Rev Immunol,2011, 29(1): 707-735.
[11]Tao JH, Zhang Y, Li XP. P2X7R: a potential key regulator of acute gouty arthritis[J]. Semin Arthritis Rheum,2013, 43(3):376-380.
[12]Vanaja SK, Rathinam VA, Fitzgerald KA. Mechanisms of inflammasome activation: recent advances and novel insights[J].Trends Cell Biol,2015, 25(5): 308-315.
[13]王璐,李璐,陈光亮.NALP3炎性体在痛风中的作用与药物治疗研究进展[J].生命科学,2016,28(3):405-408.
[14]陈光亮,周媛凤,张颖.治疗痛风和高尿酸血症药物研究进展[J].中国临床药理学与治疗学.2017,22(1):104-109.
[15]中华医学会风湿病学分会. 2016中国痛风指南[J].中华内科杂志, 2016, 55(11):892-899.
[16]Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout[J]. J Inflamm Res, 2011, 4(1):39-49. |